VetInject A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  13.8% 7.9% 7.9% 14.3% 9.6%  
Credit score (0-100)  17 31 30 14 24  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  -0.0 0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8

Net sales  0 0 0 0 0  
Gross profit  -136 -143 -139 -155 -135  
EBITDA  -136 -143 -139 -155 -135  
EBIT  -163 -170 -166 -182 -155  
Pre-tax profit (PTP)  -180.1 -191.0 -197.3 -218.8 -187.3  
Net earnings  -180.1 -191.0 -197.3 -218.8 -187.3  
Pre-tax profit without non-rec. items  -180 -191 -197 -219 -187  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -90.4 319 121 -97.5 -285  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 901  
Balance sheet total (assets)  408 939 883 792 783  

Net Debt  -13.8 -120 -94.7 -30.3 899  
 
See the entire balance sheet

Volume 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -136 -143 -139 -155 -135  
Gross profit growth  3.4% -4.8% 2.4% -11.3% 12.8%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  408 939 883 792 783  
Balance sheet change%  -12.3% 130.0% -6.0% -10.3% -1.2%  
Added value  -163.1 -169.7 -166.2 -181.9 -155.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -54 -54 -54 -54 -40  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  119.8% 118.9% 119.4% 117.4% 115.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -33.8% -23.6% -18.2% -20.5% -15.9%  
ROI %  -357.9% -106.5% -75.6% -300.0% -34.5%  
ROE %  -72.3% -52.6% -89.7% -47.9% -23.8%  

Solidity 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
Equity ratio %  -18.1% 33.9% 13.7% -11.0% -26.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  10.1% 84.3% 68.0% 19.6% -665.4%  
Gearing %  0.0% 0.0% 0.0% 0.0% -316.2%  
Net interest  0 0 0 0 0  
Financing costs %  2,322.9% 0.0% 0.0% 0.0% 7.1%  

Liquidity 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
Quick Ratio  0.0 0.9 0.7 0.5 0.5  
Current Ratio  0.0 0.9 0.7 0.5 0.5  
Cash and cash equivalent  13.8 120.3 94.7 30.3 1.2  

Capital use efficiency 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  296.6 283.5 295.4 262.6 410.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -482.7 -46.7 -217.0 -408.9 -574.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/8
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0